Stellamune One Vet. 4,5-5,2 log10/dosis injektionsvæske, emulsion Denmaki - Kidenmaki - Lægemiddelstyrelsen (Danish Medicines Agency)

stellamune one vet. 4,5-5,2 log10/dosis injektionsvæske, emulsion

elanco gmbh - mycoplasma hyopneumoniae, stamme nl1042 (inaktiveret) - injektionsvæske, emulsion - 4,5-5,2 log10/dosis - svin

Mycobac Uno Vet. Min. 1,0 ELISA un/ml injektionsvæske, suspension Denmaki - Kidenmaki - Lægemiddelstyrelsen (Danish Medicines Agency)

mycobac uno vet. min. 1,0 elisa un/ml injektionsvæske, suspension

salfarm danmark a/s - mycoplasma hyopneumoniae, stamme atcc 25095, antigen (inaktiveret) - injektionsvæske, suspension - min. 1,0 elisa un/ml - svin

Mhyogen Vet. 5,5 ELISA enheder/ml injektionsvæske, emulsion Denmaki - Kidenmaki - Lægemiddelstyrelsen (Danish Medicines Agency)

mhyogen vet. 5,5 elisa enheder/ml injektionsvæske, emulsion

ceva-phylaxia co. ltd. - mycoplasma hyopneumoniae, inaktiveret - injektionsvæske, emulsion - 5,5 elisa enheder/ml - svin

Mycobac Hyo Vet. Min 1,0 ELISA enh/ml injektionsvæske, suspension Denmaki - Kidenmaki - Lægemiddelstyrelsen (Danish Medicines Agency)

mycobac hyo vet. min 1,0 elisa enh/ml injektionsvæske, suspension

salfarm danmark a/s - mycoplasma hyopneumoniae, stamme atcc 25095, antigen (inaktiveret) - injektionsvæske, suspension - min 1,0 elisa enh/ml - svin

Suvaxyn M. Hyo Mono injektionsvæske, emulsion Denmaki - Kidenmaki - Lægemiddelstyrelsen (Danish Medicines Agency)

suvaxyn m. hyo mono injektionsvæske, emulsion

zoetis animal health aps - mycoplasma hyopneumoniae, stamme p-5722-3 (inaktiveret) - injektionsvæske, emulsion - svin

Pandemic influenza vaccine H5N1 AstraZeneca (previously Pandemic influenza vaccine H5N1 Medimmune) Umoja wa Ulaya - Kidenmaki - EMA (European Medicines Agency)

pandemic influenza vaccine h5n1 astrazeneca (previously pandemic influenza vaccine h5n1 medimmune)

astrazeneca ab - reassortant influenzavirus (levende svækket) af følgende stamme: a / vietnam / 1203/2004 (h5n1) stamme - influenza, human - vacciner - profylakse af influenza i en officielt erklæret pandemisk situation hos børn og unge fra 12 måneder til under 18 år. pandemic influenza vaccine h5n1 astrazeneca bør anvendes i overensstemmelse med officielle retningslinjer.

Spikevax (previously COVID-19 Vaccine Moderna) Umoja wa Ulaya - Kidenmaki - EMA (European Medicines Agency)

spikevax (previously covid-19 vaccine moderna)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vacciner - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

Adjupanrix (previously Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals) Umoja wa Ulaya - Kidenmaki - EMA (European Medicines Agency)

adjupanrix (previously pandemic influenza vaccine (h5n1) (split virion, inactivated, adjuvanted) glaxosmithkline biologicals)

glaxosmithkline biologicals s.a. - splittet influenzavirus, inaktiveret, indeholdende antigen: a / vietnam / 1194/2004 (h5n1) som brugt belastning (nibrg-14) - influenza, human; immunization; disease outbreaks - vacciner - prophylax af influenza i en officielt erklæret pandemisk situation. pandemic influenza vaccine bør anvendes i overensstemmelse med officielle retningslinjer.

Prepandemic Influenza Vaccine (H5N1) (Split Virion, Inactivated, Adjuvanted) GlaxoSmithKline Biologicals Umoja wa Ulaya - Kidenmaki - EMA (European Medicines Agency)

prepandemic influenza vaccine (h5n1) (split virion, inactivated, adjuvanted) glaxosmithkline biologicals

glaxosmithkline biologicals s.a. - splittet influenzavirus, inaktiveret, indeholdende antigen: a / vietnam / 1194/2004 (h5n1) som brugt belastning (nibrg-14) - influenza, human; immunization; disease outbreaks - vacciner - aktiv immunisering mod h5n1-subtype af influenza a-virus. denne angivelse er baseret på immunogenicitet data fra raske forsøgspersoner i alderen fra 18 år og op efter administration af to doser vaccine, der er fremstillet af en/vietnam/1194/2004 nibrg-14 (h5n1) (se afsnit 5. prepandemic influenza vaccine (h5n1) (split virion, inaktiveret, adjuvanted) glaxosmithkline biologicals 3. 75 µg bør anvendes i overensstemmelse med officielle retningslinjer.

Jcovden (previously COVID-19 Vaccine Janssen) Umoja wa Ulaya - Kidenmaki - EMA (European Medicines Agency)

jcovden (previously covid-19 vaccine janssen)

janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - vacciner - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. brug af denne vaccine bør være i overensstemmelse med de officielle anbefalinger.